Low‐Molecular‐Weight Heparin for the Treatment of Deep Vein Thrombosis

Low‐molecular‐weight heparin has been studied for the treatment of deep vein thrombosis in the inpatient setting and more recently in the outpatient setting. It is as safe and effective as unfractionated heparin and is effective when administered subcutaneously once or twice a day. Its bioavailability nears 100% and it has a longer half‐life than unfractionated heparin, resulting in a prolonged anticoagulant effect. A reduction in thrombocytopenia and bleeding complications with low‐molecular‐weight heparin has been reported. Laboratory monitoring is unnecessary. Low‐molecular‐weight heparin provides the opportunity for home therapy.